MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2643-3230.bcd-25-0062

Медицинская библиотека · Blood cancer discovery · 2026

Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Frenking Jan H, Riedhammer Christine, Hielscher Thomas, Schaefers Christoph, Leypoldt Lisa B, Harzer Marie, Sedloev David, Landrin Valentine, Kehl Niklas, Friedrich Mirco J, Zhou Xiang, Steinhardt Maximilian, Weis Philipp, Mersi Julia, Waldschmidt Johannes, Weinhold Niels, Kortüm K Martin, Müller-Tidow Carsten, Einsele Hermann, Sauer Sandra, Weisel Katja, Richardson Tim, Teipel Raphael, Rasche Leo, Raab Marc S

СтатьяПеревод пока не подготовлен

Аннотация

UNLABELLED: The significant clinical benefit of bispecific T-cell engagers (TCE) for the treatment of relapsed/refractory multiple myeloma (RRMM) may be offset by serious toxicities and treatment failure. Risk scores such as the CAR-HEMATOTOX (HTX), Endothelial Activation and Stress Index (EASIX), and modified EASIX (m-EASIX) can identify patients at risk for complications before chimeric antigen receptor (CAR) T-cell therapy, but their utility prior to TCE therapy remains elusive. We analyzed associations with outcomes and toxicities in independent discovery (n = 123) and validation (n = 155) cohorts treated with TCEs. Patients with HTX ≥3 or m-EASIX > median (>0.86) had a significantly increased risk of prolonged hospitalization, antibiotic treatment, and fever during step-up dosing. We also observed associations with cytopenias requiring therapeutic intervention, higher severe infection and intervention densities, as well as inferior response rates and reduced progression-free and overall survival. Our findings highlight the potential of these clinical scores to improve risk stratification before TCE therapy.

SIGNIFICANCE: Scores such as HTX, EASIX, and m-EASIX have emerged as helpful tools to enable risk stratification before CAR T-cell therapy. In this study, we demonstrate their utility in patients with RRMM receiving TCEs. HTX ≥3 and m-EASIX > median (>0.86) proved to be risk markers for infections, therapeutic interventions, and poor outcomes. See related commentary by Banerjee and Dhodapkar, p. 345.

Для цитирования: Frenking Jan H, Riedhammer Christine, Hielscher Thomas, Schaefers Christoph, Leypoldt Lisa B, Harzer Marie, Sedloev David, Landrin Valentine, Kehl Niklas, Friedrich Mirco J, Zhou Xiang, Steinhardt Maximilian, Weis Philipp, Mersi Julia, Waldschmidt Johannes, Weinhold Niels, Kortüm K Martin, Müller-Tidow Carsten, Einsele Hermann, Sauer Sandra, Weisel Katja, Richardson Tim, Teipel Raphael, Rasche Leo, Raab Marc S. Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.. Blood cancer discovery. 2026. DOI: 10.1158/2643-3230.bcd-25-0062.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.